Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: a post hoc analysis.

Diabetes, obesity & metabolism(2022)

引用 3|浏览2
暂无评分
摘要
JJM has received grants from MSD, Novo Nordisk and Sanofi; and lecture/other fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, MSD, Novo Nordisk, Sanofi and Servier. EM reports serving on scientific advisory boards; and consulting for, lecturing for and/or receiving research grants from Eli Lilly, Menarini, MSD, Novo Nordisk, Roche and Sanofi. REP reports lecture and consulting fees from AstraZeneca; consulting fees from Boehringer Ingelheim, Eisai, GlaxoSmithKline and Mundipharma; grants, lecture and consulting fees from Glytec, Janssen, Novo Nordisk, Pfizer and Takeda; grants from Lexicon Pharmaceuticals; and grants and consulting fees from Ligand Pharmaceuticals, Lilly, Merck and Sanofi-Aventis US outside of the submitted work. REP's fees for services were paid directly to AdventHealth, a non-profit organization. AYYC reports honoraria from Abbott, Amgen, AstraZeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GlaxoSmithKline, HLS Therapeutics, Insulet, Janssen, Medtronic, Merck, Novo Nordisk, Pfizer, Sanofi and Takeda. LB, BM and LW are employees, and LB and LW are shareholders, of Novo Nordisk A/S. The peer review history for this article is available at https://publons.com/publon/10.1111/dom.14957. Data are available upon reasonable request. Data will be shared with bona fide researchers submitting a research proposal approved by the independent review board. Access request proposals can be found at novonordisk-trials.com. Data will be made available after research completion, and approval of the product and product use in the European Union and the USA. Individual participant data will be shared in data sets in a de-identified/anonymized format. TABLE S1. Mean change from baseline in body weight (kg) by presence or absence of GI AEs at the end of treatment. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
更多
查看译文
关键词
GLP-1 analogue,incretin therapy,phase 3 study,type 2 diabetes
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要